Monthly Archives: October 2016

10th Oswestry Cartilage Symposium

“The Quality of Cartilage Repair”

Thursday 24th and Friday 25th November 2016

The Robert Jones & Agnes Hunt Orthopaedic Hospital

A Symposium on the outcome measures of healing and healed cartilage Quantification of healing is essential for progress in chondrocyte and stem cell techniques of repair and all attempts to slow the progression of arthritis. The focus of this two day symposium is on imaging and histology of cartilage in humans and on novel quantitative approaches in animal models or in vitro techniques of cartilage formation. oswestry

2017 Rare Disease Day theme is announced


logo-rare-disease-dayThe Theme is research see here

In EU programmes alone, €620 million were assigned to rare disease research between 2007 and 2013. Money continues to be allocated to rare disease research through the EU with €200 million assigned between 2014 and 2015, making rare disease research continuously attractive to scientists. In parallel, EU Member States have grown their research budgets.

Due to the rarity and diversity of rare diseases, research needs to be international to ensure that experts, researchers and clinicians are connected, that clinical trials are multinational and that patients can benefit from the pooling of resources across borders. Initiatives such as the European Reference Networks (networks of centres of expertise and healthcare providers that facilitate cross-border research and healthcare), the International Rare Disease Research Consortium and the EU Framework Programme for Research and Innovation Horizon 2020 support international, connected research.

Rare disease research reduces costs for healthcare systems. As a result of research, a rare disease patient who is diagnosed or properly treated no longer needs irrelevant tests, ineffective treatment or hospital visits. In addition, research on specific rare diseases often shines a light on more prevalent diseases. Pioneering approaches in rare disease research often benefit the much wider public affected by more common diseases.